J.R. Zanchetta receives consulting fees and is a member of Advisory Boards for Amgen,

Eli Lilly, GSK, Merck, Pfizer, and Servier. He has also received grant/research support RG-7388 research buy from Amgen, Eli Lilly, Merck, Pfizer, GSK, and Procter and Gamble. A. Racewicz has no disclosures. C. Roux has received honoraria and research grants from the Alliance for Better Bone Health. C.L. Benhamou is a consultant and/or speaker for Amgen, Merck, Novartis, Roche, and Servier; he also received funding from Amgen, Servier, Roche, and UCB Pharma. Z. Man receives consulting fees as member of Novartis’ Steering Committee and for Advisory Boards of GSK and sanofi-aventis; is speaker for Novartis, Roche, sanofi-aventis, and Servier; and also received grant/research support from Amgen, Eli Lilly, Merck, Novartis, NPS, GSK, Roche, sanofi-aventis, Servier, and Procter and Gamble. R.A. Eusebio is a full-time BAY 63-2521 purchase employee and owns stocks of Procter and Gamble Company. J.F. Beary was an employee of Procter and Gamble at the time of the study and is now retired from P&G; jfb 1-29-2011]. D.E. Burgio is a full-time employee of Procter and Gamble. E. Matzkin has no disclosures. S. Boonen has received research support from Amgen, Merck, sanofi-aventis, Procter

and Gamble Pharmaceuticals, Warner Chilcott, and Servier. P. Delmas is deceased. Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. Appendix The other principal investigators in this study are: Argentina—C.

Magaril, Buenos Aires; C. Mautalen, Buenos Aires; H. Salerni, Buenos Aires. Australia—G. Nicholson, Geelong, Victoria. Belgium—Y. Boutsen, Dichloromethane dehalogenase Mont-Godinne; J.-P. Devogelaer, Brussels; J.-M. Kaufman, Gent. Canada—J. Brown, Quebec; D. see more Hanley, Calgary; W. Olszynski, Saskatoon; L.-G. Ste.-Marie, Quebec. Estonia—K. Maasalu, Tartu; K.-L. Vahula, Pärnu; I. Valter, Tallinn. Finland—J. Heikkinen, Kemi; H. Kroger, Kuopio; L. Makinen, Turku; M. Valimaki, Helsinki. France—P. Fardellone, Amiens; M. Laroche, Toulouse; G. Weryha, Vandoeuvre. Hungary—T. Hidvégi, Gyor; C. Horvath, Budapest; L. Koranyi, Balatonfüred; P. Lakatos, Budapest. Lebanon—G. E.-H. Fuleihan, Beirut. Norway—J. Halse, Oslo; E. Ofjord, Paradis; T. Sordal, Trondheim. Poland—J. Badurski, Bialystok; E. Marcinowska-Suchowierska, Warszawa; J. Pazdur, Warszawa. Spain—J. Farrerons, Barcelona; C. L. Tonkin, Madrid; M. M. Torres, Granada. USA—M. Bolognese, Bethesda, MD; R. Recker, Omaha, NE; C. Recknor, Gainesville, GA; N. Watts, Cincinnati, OH. References 1. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial.